Talk — Anonymous Pharma Rep Forum

117 anonymous posts from pharmaceutical sales representatives across 112 companies.

Recent Posts

• FieldPulse prompt: How are Lilly and Novo teams preparing for the July 1 Medicare GLP-1 access conversation? — Eli Lilly · 0 upvotes · 0 comments
• FieldPulse prompt: How does Trodelvy's first-line TNBC approval change the field conversation? — Gilead Sciences · 0 upvotes · 0 comments
• FieldPulse prompt: What, if anything, does the Apogee deal change about how AbbVie reps think about the next phase of immunology growth? — AbbVie · 0 upvotes · 0 comments
• FieldPulse prompt: What does quota pressure look like in Lilly field roles when demand, supply, and access do not line up? — Eli Lilly · 0 upvotes · 0 comments
• FieldPulse prompt: How has access friction changed recently for Novo Nordisk reps? — Novo Nordisk · 0 upvotes · 0 comments
• The 'High Risk/High Reward' trap at Bayer - is anyone actually winning? — Bayer · 0 upvotes · 0 comments
• Biogen Reps: The 'Pharmacy Partnership' Pivot - Are We Sales Reps or Managed Care Liaisons Now? — Biogen · 0 upvotes · 0 comments
• The 'Upcoming Changes' at Alexion - is anyone else getting the jitters? — Alexion (AstraZeneca) · 0 upvotes · 0 comments
• Novo Nordisk Reps: 'Areas of Opportunity' or Just Corporate Code for 'More with Less'? — Novo Nordisk · 0 upvotes · 0 comments
• Ipsen Reps: 'Areas of Opportunity' or Just Corporate Code for 'More with Less'? — Ipsen · 0 upvotes · 0 comments
• The 'Areas of Opportunity' babble at Horizon - is anyone actually buying it? — Horizon Therapeutics · 0 upvotes · 0 comments
• AstraZeneca Reps: That 'Expansion Smell' on LinkedIn? More Like 'Mirrored Territory' Reality. — AstraZeneca · 0 upvotes · 0 comments
• Why are we cutting field reps while the 'Sr. Directors' keep multiplying? — Ipsen · 0 upvotes · 0 comments
• Bayer Reps: Are PBMs the Real Gatekeepers Now? How Do We Even Sell Anymore? — Bayer · 0 upvotes · 0 comments
• Lilly's 'Innovation' - is it actually reaching the field? — Eli Lilly · 0 upvotes · 0 comments
• Eli Lilly Reps: Are We Just 'Ghost Hires' Now? No Backfills, Just Bigger Territories. — Eli Lilly · 0 upvotes · 0 comments
• The 'AI-Optimized' Micromanagement at Daiichi - is anyone else losing their mind? — Daiichi Sankyo · 0 upvotes · 0 comments
• Amgen R&D Layoffs: What Does This Mean for Our Future Pipeline? — Amgen · 0 upvotes · 0 comments
• The 'Metric Madness' at Lundbeck - is anyone else feeling the squeeze? — Lundbeck · 0 upvotes · 0 comments
• Jazz Pharmaceuticals Reps: Is This $1.3B Cost-Cutting Plan Just Another Word for Layoffs? — Jazz Pharmaceuticals · 0 upvotes · 0 comments
• The 'Pay for Performance' trap at BI - is anyone else feeling the burnout? — Boehringer Ingelheim · 0 upvotes · 0 comments
• The 'Engagement Paradox': AI for Patients, But What About Us, Bristol Myers Squibb Reps? — Bristol Myers Squibb · 0 upvotes · 0 comments
• The 'Turnover Madness' at GSK - is anyone else seeing this? — GlaxoSmithKline (GSK) · 0 upvotes · 0 comments
• GSK Blenrep Launch: High Quotas, Low Incentives - Anyone Else Feeling Screwed? — GlaxoSmithKline (GSK) · 0 upvotes · 0 comments
• 75 emails a month? Are we sales reps or spam bots now? — Lundbeck · 0 upvotes · 0 comments

Post anonymously · News · Companies